Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for ...

周三，H.C. Wainwright维持对Genmab A/S ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

AbbVie ABBV announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular ...

American Institute for Advanced Investment Management LLP boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...

周五，TD Cowen对Genmab A/S (NASDAQ:GMAB)的股票保持中立立场，重申持有评级，目标价为$30.00。该公司的预测与市场普遍共识一致，预计Genmab的癌症药物Darzalex在第三季度的全球销售额将达到约30亿美元，接近29亿美元的共识预期。这一预测得到了数据的支持，数据显示美国销售额可能达到17亿美元。 TD Cowen的分析师还预计Epkinly第三季度销售额为76 ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.